[1] Hatakeyama S, Watanabe M, Fujii Y, et al.Targeted Destruction of c-Myc by an Engineered Ubiquitin Ligase Suppresses Cell Transformation and Tumor Formation[J] .Cancer Res, 2005, 65(17) :7874-7879. [2] 黄鹤, 吴佩, 洪书剑, 等.胰腺癌Bx-PC3 细胞 Survivin基因 shRNA 质粒表达载体的构建[J] .中国临床药理学与治疗学, 2006, 11(6) :655-658. [3] 聂立功, 潘中宝, 许松, 等.薏苡仁提取物对人肺鳞癌细胞端粒酶的影响[J] .中国临床药理学与治疗学,2003, 8(4) :419-431. [4] 黄浩, 涂欣, 余南才, 等.c-Myc 靶向小分子干扰 RNA抑制人直肠癌Colo320 细胞增殖的实验研究[J] .中国临床药理学与治疗学, 2006, 11(11) :1301-1304. [5] Kondo Y, Koga S, Komata T, et al.Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component[J] .Oncogene, 2000, 19(18) :2205-2211. [6] Rot hermundK, Rogulski K, Fernandes E, et al. c-Myc independent restoration of multiple phenotypes by two c-Myc target genes with overlapping functions[J] .Cancer Res, 2005, 65(6) :2097-2107. [7] Luo J, Su F, Chen D, et al.Deacetylation of p53 modu-lates its effect on cell growth and apoptosis[J] .Nature,2000, 408(6810) :377-381. [8] Tyner SD, Choi J, Jones SH. p53 mutant mice that display early ageing- associated pHenotypes[J] .Nature, 2002,415(6867) :45-53. [9] Liu JP.Telomerase:not just black and white, but shades of gray[J] .Mol Cell Biol Res Commun, 2000, 3(3) :129-135. [10] HemannMT, Bric A, Teruya J, et al. Evasion of the p53 tumour surveillance network by tuour derived MYC mutants[J] .Nature, 2005, 436(7052) :787-795. [11] Latil A, Vidaud D, Valeri A, et al.hTERT expression correlates with MYC over-expression in human prostate cancer[J] .Int J Cancer, 2000, 89(2) :172-176. |